Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cytokine levels gauge response to interferon-alpha in HCV-infected patients

Ethnicity appears to contribute to the variable immune responses among patients infected with hepatitis C and to outcome following interferon therapy, according to research published in the November issue of the Journal of Medical Virology.

News image

fiogf49gjkf04

Researchers from Richmond, Virginia, USA, investigated whether ethnicity and cytokine production can be used to gauge the response of patients with hepatitis C to interferon-alpha therapy.

Interferon (IFN) is the primary treatment for hepatitis C virus (HCV). However, the long-term success rate is low, particularly for African Americans relative to Caucasians, and may be due to differential immune abilities.

The study compared cytokine production from phytohemagglutinin-stimulated peripheral blood from 25 healthy and 40 HCV-infected African Americans and Caucasians.

HCV patients were designated as IFN responders or nonresponders, based on outcome after therapy.

The researchers found that ethnicity and genotype were associated with IFN response.

IFN responders were 100% Caucasian, whereas nonresponders were 67% Caucasian and 33% African American.

Cytokine production from healthy individuals showed ethnic variation in cytokine levels. Healthy African Americans were found to produce greater amounts of IL-2 and TNF-alpha, and less IL-10 than healthy Caucasians. In contrast, IFN-gamma and TGF-beta levels were equivalent.

Pretherapy cytokine production among HCV patients showed a similar pattern of ethnic variation.

No African Americans responded to IFN therapy.
Journal of Medical Virology

Among nonresponders, African Americans produced more IL-2 and TNF-alpha than Caucasians. On the contrary, Caucasian responders produced subnormal levels of IL-10 and TGF-beta.

Since all African Americans failed IFN therapy, cytokine production could not be compared with therapeutic outcome.

However, comparison of cytokine production among Caucasians showed that responders produced less IL-10 and more TGF-beta than nonresponders. It also predicted Caucasian nonresponders with 83% sensitivity and 96% specificity.

Pam Kimball, of the Department of Surgery at the Medical College of Virginia at the Virginia Commonwealth University, said on behalf of the group, "It appears that ethnicity may contribute to variable immune responses and therapeutic outcome.

"The cytokine profile among African Americans suggests a more robust immune response, which may complicate therapy with IFN.

"In contrast, the subnormal cytokine production among Caucasian responders may be more permissive to IFN therapy."

"Pretherapy cytokine production may allow prediction of drug resistance among Caucasians," it was concluded.

J Med Virol 2001; 65: 510-16
28 November 2001

Go to top of page Email this page Email this page to a colleague

 24 November 2017 
Osteoporotic fractures in Barrett's esophagus
 24 November 2017 
Center ERCP volume and procedure success
 24 November 2017 
Adipokines and IBD
 23 November 2017 
Pharmacological management of GERD
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Distance travelling for rectal cancer outcomes
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 21 November 2017 
Prepregnancy obesity and maternal mortality
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Autoimmune pancreatitis in children
 01 November 2017 
Heartburn relief in adolescents with GERD
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us